This webcast features: Kyle Deluca, Senior Scientist, Engineering & Felix Milman, Specialist, Engineering, Merck. In an effort to improve the efficiency of large molecule process characterization work, the Bioconjugation and Chemistry Commercialization team at Merck looked to automate steps involved in the production of its vaccine pipeline candidates. The actions taken by the team included installation of an automated reactor system that would provide new process capability and allow reactions to be completed outside of business hours, while improving process…